ReviewInternal and emergency medicine2018
Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism.
Review in Internal and emergency medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The right place of interleukin-1 inhibitors in the treatment of Behçet's syndrome: a systematic review.Rheumatology international · 2019Pooled it
- Longitudinal cardiac magnetic resonance imaging following clinical response to rilonacept and prior to recurrence upon treatment suspension: a RHAPSODY subgroup analysis.European heart journal. Cardiovascular Imaging · 2024Trial
- Cardioimmunology of Myocarditis: Targeting the IL-1 Pathway.Current cardiology reports · 2026Review
- Idiopathic recurrent pericarditis in children: a tertiary care cohort highlighting the emergence and effectiveness of interleukin-1 blockade.European journal of pediatrics · 2026Article
- A Rare Presentation of Subacute Constrictive Pericarditis Secondary to Rhinovirus Infection: A Case Report.Cureus · 2026Article
- Causal Association Between Plasma Proteins and Pericarditis: A Mendelian Randomization Study With Therapeutic Target Identification.Mediators of inflammation · 2026Article
- Etiologies, fluid characteristics, and outcomes of pericardiocentesis: a five-year retrospective study from a single center.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2025Article
- Old and New Biomarkers in Idiopathic Recurrent Acute Pericarditis (IRAP): Prognosis and Outcomes.Current cardiology reports · 2025Review
- Advances in the Multimodality Imaging and Management of Recurrent Pericarditis: A Contemporary Review.Current cardiology reports · 2024Review
- Can Asthma Cause Pericardial Effusion? Insights Into an Intriguing Association.Texas Heart Institute journal · 2023Article
- Rilonacept (Interleukin-1 Inhibition) for the Treatment of Pericarditis.Current cardiology reports · 2022Review
- Emerging Therapies for Recurrent Pericarditis: Interleukin-1 inhibitors.Journal of the American Heart Association · 2021Review
- Autoimmune and Autoinflammatory Pericarditis: Definitions and New Treatments.Current cardiology reports · 2021Review
- Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID-19 pneumonia and moderate hyperinflammation. A retrospective cohort study.Internal and emergency medicine · 2021Observational
- Recurrent pericarditis: an update on diagnosis and management.Internal and emergency medicine · 2021Review
- The Role of Rilonacept in Recurrent Pericarditis.Heart international · 2021Review
- Multiple Cytokines Elevated in Patients with Keloids: Is It an Indication of Auto-Inflammatory Disease?Journal of inflammation research · 2021Article
- Anakinra for the Treatment of COVID-19-Associated Pericarditis: A Case Report.Cardiovascular drugs and therapy · 2020Article
- Efficacy and safety of rilonacept for recurrent pericarditis: results from a phase II clinical trial.Heart (British Cardiac Society) · 2020Article
- Novel Pharmacotherapies for Recurrent Pericarditis: Current Options in 2020.Current cardiology reports · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recurrent pericarditis is one of the most frequent pericardial diseases, affecting up to 30% of the patients who have experienced acute pericarditis. While the diagnosis of acute pericarditis is sometime straight forward, its etiology and therapeutic management are still a challenge for physicians. In developed countries, the idiopathic form is the most frequent, and the search for an infectious etiology is almost invariably negative. Nevertheless, since standard treatment with nonsteroidal anti-inflammatory drugs and colchicine is not always able to neutralize pericardial inflammation in recurrent pericarditis, anakinra, an IL-1 receptor antagonist, has been proposed as a possible therapeutic alternative for refractory forms. IL-1 is a cytokine that exerts a pivotal role in innate immunity and in the pathogenesis of some autoimmune diseases, such as rheumatoid arthritis, and in autoinflammatory disorders, as familial Mediterranean fever and cryopyrin-associated periodic syndromes. The successful management of patients with acute idiopathic recurrent pericarditis (IRP) needs a teamwork approach, where cardiologists, rheumatologists, clinical immunologists and internists are involved. In this review, we will discuss the clinical and therapeutical challenges of IRP both in adults and children from a clinical practice standpoint. We will also briefly illustrate the main pathogenic mechanisms of IRP to provide internists and cardiologists with the rationale for approaching the use of anakinra in selected clinical cases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.